Trial reportHeart and vessels2012
Prospective, randomized, single-blind comparison of effects of 6 months' treatment with atorvastatin versus pravastatin on leptin and angiogenic factors in patients with coronary artery disease.
Trial report in Heart and vessels, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 35 citations in OpenAlex.
- Cardiac rehabilitation may influence leptin and VEGF A crosstalk in patients after acute coronary syndrome.Scientific reports · 2022Trial
- New Insights on the Relationship between Leptin, Ghrelin, and Leptin/Ghrelin Ratio Enforced by Body Mass Index in Obesity and Diabetes.Biomedicines · 2021Article
- Novel Therapeutical Approaches to Managing Atherosclerotic Risk.International journal of molecular sciences · 2021Review
- Effect of high fat diet and excessive compressive mechanical force on pathologic changes of temporomandibular joint.Scientific reports · 2020Article
- Endocrine and metabolic disorders in patients with Gaucher disease type 1: a review.Orphanet journal of rare diseases · 2019Review
- Thyroid volumes and serum VEGF levels in dyslipidemic patients: effects of statin treatmentTurkish journal of medical sciences · 2019Article
- Leptin, cardiovascular diseases and type 2 diabetes mellitus.Acta pharmacologica Sinica · 2018Review
- Statins decrease leptin expression in human white adipocytes.Physiological reports · 2018Article
- Differences between perivascular adipose tissue surrounding the heart and the internal mammary artery: possible role for the leptin-inflammation-fibrosis-hypoxia axis.Clinical research in cardiology : official journal of the German Cardiac Society · 2016Article
- Leptin-Induced JAK/STAT Signaling and Cancer Growth.Vaccines · 2016Review
- Clinical significance of Angiopoietin-1 in Behcet's disease patients with vascular involvement.Heart and vessels · 2016Article
- Impact of lysophosphatidylcholine on survival and function of UEA-1(+)acLDL (+) endothelial progenitor cells in patients with coronary artery disease.Heart and vessels · 2015Article
- Effect of rosuvastatin on hyperuricemic rats and the protective effect on endothelial dysfunction.Experimental and therapeutic medicine · 2014Article
- Hepatocyte growth factor, a biomarker of macroangiopathy in diabetes mellitus.World journal of diabetes · 2014Review
- Lipid-lowering and anti-inflammatory effect of ezetimibe in hyperlipidemic patients with coronary artery disease.Heart and vessels · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptin has been reported to exert an atherosclerotic effect by regulating expression of angiogenic factors that have been implicated in the pathogenesis of coronary artery disease (CAD). The purpose of this study was to investigate whether lipid-lowering therapy (LLT) with statins could affect leptin levels and angiogenic factors in patients with CAD. This study included 76 patients with CAD and 15 subjects without CAD (non-CAD). CAD patients were randomized to 6 months of intensive LLT with atorvastatin or moderate LLT with pravastatin. Plasma leptin, angiopoetin-2 (Ang-2), hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) levels were measured prior to statin therapy (baseline) and after 6 months. Baseline levels of leptin, Ang-2, HGF and VEGF were higher in the CAD group than in the non-CAD group (all P < 0.05). Treatment with intensive LLT decreased leptin, Ang-2, HGF and VEGF levels, whereas moderate LLT did not change these levels. This study suggests that LLT with atorvastatin decreases leptin levels and angiogenic factors in patients with CAD, possibly contributing to the beneficial effects of LLT with atorvastatin in CAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.